Ondansetron Dydrochloride Dihydrate Aurobindo

Ondondansetron, the active ingredient in Ondansetron Dydrochloride Dihydrate Aurobindo, is a 5-HT3 receptor antagonist presented as a 5 mg tablet for oral use. It helps prevent nausea and vomiting caused by chemotherapy, radiation therapy, and surgery.

GNH USA supplies Ondansetron Dydrochloride Dihydrate Aurobindo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Ondansetron is a selective serotonin 5‑HT3 receptor antagonist used in the management of nausea and vomiting across several clinical pathways. - Chemotherapy‑induced nausea and vomiting (CINV): reduces the frequency and severity of acute and delayed episodes. - Radiation‑induced nausea and vomiting (RINV): helps control nausea during and after radiotherapy. - Post‑operative nausea and vomiting (PONV): decreases the incidence of nausea and vomiting after surgical procedures.

Common Side Effects: - Headache: mild to moderate intensity. - Constipation: occasional bowel movement difficulty. - Diarrhoea: loose stools in a minority of patients. - Fatigue: general tiredness or lack of energy. - Dizziness: sensation of light‑headedness. - Injection site pain (if administered parenterally): localized discomfort.

Serious or Rare Side Effects: - Cardiac arrhythmia: QT‑interval prolongation that may lead to irregular heart rhythm. - Severe allergic reaction: rash, itching, swelling, or breathing difficulty. - Serotonin syndrome: rare but potentially life‑threatening condition when combined with other serotonergic agents. - Hepatic dysfunction: elevated liver enzymes indicating liver stress. - Blood dyscrasias: uncommon reductions in white blood cells or platelets. - Neuroleptic malignant‑like syndrome: extremely rare neurological emergency.

Before prescribing Ondansetron, consider the following precautions: - Cardiac assessment: evaluate baseline ECG in patients with known heart disease or electrolyte abnormalities. - Electrolyte monitoring: correct potassium, magnesium, or calcium imbalances that could predispose to QT prolongation. - Drug interactions: review concomitant medications that affect cardiac conduction or serotonin levels. - Pregnancy and lactation: weigh benefits against potential risks; use only if clearly needed. - Renal/hepatic impairment: dose adjustment may be required in severe dysfunction. - Store at below 25°C: keep in the original container, protect from moisture and direct sunlight.

Ondansetron may interact with several medicines, requiring careful management. Major Interactions (Avoid): - Amiodarone: combined use can markedly increase QT‑interval prolongation risk. - Certain anti‑arrhythmics (e.g., sotalol, quinidine): additive effects on cardiac repolarisation. - Serotonergic agents (e.g., tramadol, linezolide) when used in high doses: heightened serotonin‑syndrome risk. Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., erythromycin, ketoconazole): may raise ondansetron plasma levels. - CYP2D6 substrates (e.g., metoprolol, codeine): potential alteration of their metabolism. - Anticholinergic drugs: may blunt the anti‑emetic effect. - Diuretics: electrolyte shifts can influence QT interval. - Oral contraceptives: rare reports of reduced efficacy.